Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 776 to 800 of 881

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism	TA261	25 July 2012	25 July 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2	TA257	27 June 2012	27 June 2012
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer	TA258	27 June 2012	27 June 2012
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine	TA260	27 June 2012	27 June 2012
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis	TA254	25 April 2012	25 April 2012
Tocilizumab for the treatment of rheumatoid arthritis	TA247	22 February 2012	22 February 2012
Rituximab for the first-line treatment of stage III-IV follicular lymphoma	TA243	25 January 2012	25 January 2012
Apixaban for preventing venous thromboembolism after hip or knee replacement surgery	TA245	25 January 2012	25 January 2012
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy	TA242	25 January 2012	25 January 2012
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer	TA118	24 January 2007	1 January 2012
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis	TA238	14 December 2011	14 December 2011
Fulvestrant for the treatment of locally advanced or metastatic breast cancer	TA239	14 December 2011	14 December 2011
Mifamurtide for the treatment of osteosarcoma	TA235	26 October 2011	26 October 2011
Ticagrelor for the treatment of acute coronary syndromes	TA236	26 October 2011	26 October 2011
Agomelatine for the treatment of major depressive episodes (terminated appraisal)	TA231	27 July 2011	27 July 2011
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma	TA228	27 July 2011	27 July 2011
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion	TA229	27 July 2011	27 July 2011
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction	TA73	26 November 2003	1 July 2011
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer	TA227	29 June 2011	29 June 2011
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs	TA225	22 June 2011	22 June 2011
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma	TA226	22 June 2011	22 June 2011
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease	TA223	25 May 2011	25 May 2011
Golimumab for the treatment of psoriatic arthritis	TA220	27 April 2011	27 April 2011
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia	TA218	23 March 2011	23 March 2011
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer	TA214	23 February 2011	23 February 2011

Results per page

10
25
50
All